| Field | Specification |
|---|---|
| Target | |
| Alternative names | N-myc-interactor;Nmi;N-myc and STAT interactor;NMI; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human NMI recombinant protein (Position: E2-E307). Human NMI shares 64% amino acid (aa) sequence identity with mouse NMI. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes N-myc-interactor (gene NMI) in human samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 35.1 kDa, and the supplier reports an observed band at about 35 kDa.
N-myc interactor (NMI) is an interferon-inducible protein that binds STAT transcription factors. After IL-2 or interferon-γ stimulation it helps recruit the coactivators CBP/p300 to STAT1 and STAT5, enhancing their transcriptional activity, and it also modulates innate antiviral signaling. It is studied in cytokine signaling and immune responses.
| Target | N-myc-interactor (gene NMI; UniProt Q13287, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 35.1 kDa |
| Observed MW | 35 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human placenta tissue, human K562 cells, human Caco-2 cells, human A431 cells, human PC-3 cells, human 293T cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human colon cancer tissue, human lung cancer tissue, human mammary cancer tissue, human placenta tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): U937 cells.
Immunogen
Recombinant human NMI fragment (Glu2–Glu307), expressed in E. coli. Sequence identity with the mouse ortholog: 64%.
Reactivity Notes
The supplier lists reactivity with human. UniProt describes N-myc-interactor as secreted and also located in the cytoplasm and nucleus. Tissue expression noted by UniProt (human): Expressed in adult spleen, liver, and kidney. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
